IOVS Molecular Human Reproduction
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2007;48:4215-4219.)
© 2007 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.07-0176
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huemer, K.-H.
Right arrow Articles by Fuchsjäger-Mayrl, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huemer, K.-H.
Right arrow Articles by Fuchsjäger-Mayrl, G.

Role of Nitric Oxide in Choroidal Blood Flow Regulation during Light/Dark Transitions

Karl-Heinz Huemer,1,2 Gerhard Garhofer,1 Tina Aggermann,1 Julia Kolodjaschna,1 Leopold Schmetterer,1,3 and Gabriele Fuchsjäger-Mayrl1,4

1From the Department of Clinical Pharmacology, the 2Center for Physiology and Pathophysiology, the 3Department of Biomedical Engineering and Physics, and the 4Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.

PURPOSE. Several studies have recently shown that a transition from light to dark is associated with a reduction in choroidal blood flow. The mechanism underlying this effect is unclear but may be related to changes in neural input. In the present study, the authors hypothesized that either the {alpha}-receptor agonist phenylephrine or the nitric oxide synthase (NOS) inhibitor L-NMMA may alter the choroidal blood flow response during a transition from light to dark.

METHODS. In 15 healthy male nonsmoking subjects, the response of choroidal perfusion was studied in a randomized placebo-controlled three-way crossover study. Phenylephrine, L-NMMA or placebo was administered on different study days, and the effect of a light/dark transition on choroidal perfusion parameters was studied. Subfoveal choroidal blood flow and fundus pulsation amplitude were assessed with laser Doppler flowmetry and laser interferometry, respectively.

RESULTS. Before drug administration, a transition from light to dark reduced both choroidal hemodynamic parameters by 11% to 20%. Neither phenylephrine nor placebo altered basal choroidal blood flow or choroidal blood flow responses to the light/dark transitions. By contrast, the NOS inhibitor L-NMMA significantly reduced basal choroidal blood flow by 20.5% ± 5.9% (P < 0.001) and basal fundus pulsation amplitude by 21.5% ± 4.8% (P < 0.001). In addition, the response of subfoveal choroidal blood flow (–6.2% ± 3.2%; P = 0.008) and fundus pulsation amplitude (–4.2% ± 2.4%; P < 0.001) to the light/dark transition was significantly diminished.

CONCLUSIONS. The present study indicates that NO plays a role in the choroidal blood flow decrease during a transition from light to dark. Given that L-NMMA is a nonspecific inhibitor of NOS, the present study does not clarify whether this NO is from endothelial or neural sources.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Association for Research in Vision and Ophthalmology